Literature DB >> 17910089

Using mouse models to explore genotype-phenotype relationship in Down syndrome.

Ahmad Salehi1, Mehrdad Faizi, Pavel V Belichenko, William C Mobley.   

Abstract

Down Syndrome (DS) caused by trisomy 21 is characterized by a variety of phenotypes and involves multiple organs. Sequencing of human chromosome 21 (HSA21) and subsequently of its orthologues on mouse chromosome 16 have created an unprecedented opportunity to explore the complex relationship between various DS phenotypes and the extra copy of approximately 300 genes on HSA21. Advances in genetics together with the ability to generate genetically well-defined mouse models have been instrumental in understanding the relationships between genotype and phenotype in DS. Indeed, elucidation of these relationships will play an important role in understanding the pathophysiological basis of this disorder and helping to develop therapeutic interventions. A successful example of using such a strategy is our recent studies exploring the relationship between failed nerve growth factor (NGF) transport and amyloid precursor protein (App) overexpression. We found that increased dosage of the gene for App is linked to failed NGF signaling and cholinergic neurodegeneration in a mouse model of DS. Herein, we discuss several mouse models of DS and explore the emergence of exciting new insights into genotype-phenotype relationships, particularly those related to nervous system abnormalities. An important conclusion is that uncovering these relationships is enhanced by working from carefully defined phenotypes to the genes responsible. 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17910089     DOI: 10.1002/mrdd.20164

Source DB:  PubMed          Journal:  Ment Retard Dev Disabil Res Rev        ISSN: 1080-4013


  22 in total

1.  The Link between Alzheimer's Disease and Down Syndrome. A Historical Perspective.

Authors:  Ahmad Salehi; J Wesson Ashford; Elliott J Mufson
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

2.  Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome.

Authors:  Alexander M Kleschevnikov; Pavel V Belichenko; Jessica Gall; Lizzy George; Rachel Nosheny; Michael T Maloney; Ahmad Salehi; William C Mobley
Journal:  Neurobiol Dis       Date:  2011-10-17       Impact factor: 5.996

Review 3.  Down syndrome and the complexity of genome dosage imbalance.

Authors:  Stylianos E Antonarakis
Journal:  Nat Rev Genet       Date:  2016-12-28       Impact factor: 53.242

Review 4.  Down syndrome: the brain in trisomic mode.

Authors:  Mara Dierssen
Journal:  Nat Rev Neurosci       Date:  2012-12       Impact factor: 34.870

5.  Genetic disorders of intellectual disability: expanding our concepts of phenotypes and of family outcomes.

Authors:  Robert M Hodapp; Elisabeth M Dykens
Journal:  J Genet Couns       Date:  2012-08-24       Impact factor: 2.537

Review 6.  Antioxidants in Down syndrome.

Authors:  Ira T Lott
Journal:  Biochim Biophys Acta       Date:  2011-12-21

Review 7.  Emerging pharmacotherapies for neurodevelopmental disorders.

Authors:  Daniel Z Wetmore; Craig C Garner
Journal:  J Dev Behav Pediatr       Date:  2010-09       Impact factor: 2.225

8.  DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.

Authors:  Jianxing Xiang; Su Yang; Ning Xin; Marta A Gaertig; Roger H Reeves; Shihua Li; Xiao-Jiang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

Review 9.  A Sonic hedgehog (Shh) response deficit in trisomic cells may be a common denominator for multiple features of Down syndrome.

Authors:  Duane G Currier; Renita C Polk; Roger H Reeves
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

10.  PCR prescreen for genotyping the Ts65Dn mouse model of Down syndrome.

Authors:  Hernan Lorenzi; Nichole Duvall; Sheila M Cherry; Roger H Reeves; Randall J Roper
Journal:  Biotechniques       Date:  2010-01       Impact factor: 1.993

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.